Messenger

Dr. Laura Shawver to be Recognized as 2024 Duane Roth Endowed Award Lecture Recipient at 20th Annual Industry/Academia Precision Oncology Symposium

Retrieved on: 
Monday, March 11, 2024
Oncology, Health, Consumer, Women, Science, Biotechnology, Diagnosis, Ovarian cancer, Cell, Disease, Oncogene, UC, Research, Cancer, Messenger, Woman, Therapy, Cytokine, AAA, Pharmaceutical industry

The Duane Roth Endowed Lecture Committee today announced that it will recognize Laura Shawver, Ph.D., as the 2024 Award Lecture recipient.

Key Points: 
  • The Duane Roth Endowed Lecture Committee today announced that it will recognize Laura Shawver, Ph.D., as the 2024 Award Lecture recipient.
  • The award will be presented by San Diego Mayor Todd Gloria during the 20th Annual Industry/Academia Precision Oncology Symposium on March 21 in La Jolla, California.
  • Dr. Laura Shawver is a healthcare pioneer who has created new paradigms in cancer research and treatment through her roles as a scientist, leader, patient and patient advocate.
  • As an early career scientist, she conducted research on oncogenes, growth factors and signal transduction pathways.

Cellecta, Inc. Launches DriverMap™ Adaptive Immune Receptor (AIR) Human RNA Spike-In Controls to Ensure Consistent Quality and Optimal Performance of TCR and BCR Profiling Assays

Retrieved on: 
Thursday, April 4, 2024
PCR, QC, Gene, Data analysis, RT, Bias, BCR, Calibration, NGS, Biomarker, Research, RNA, Messenger, Workflow, Immunity, TCR, Collection, AIR, Vaccine

MOUNTAIN VIEW, Calif., April 4, 2024 /PRNewswire/ -- Cellecta, Inc. today announced the launch of the DriverMap™ Adaptive Immune Receptor (AIR) Human RNA Spike-In Premixed Controls, the first commercially available collection of synthetic mRNA constructs that can serve as universal controls for commercial or home-brewed AIR repertoire sequencing (AIR-Seq, TCR-seq and BCR-seq) assays based on multiplex RT-PCR or 5' RACE PCR techniques.

Key Points: 
  • The first-to-market DriverMap™ AIR RNA TCR/BCR spike-in calibration controls measure the accuracy, sensitivity, and linear range of sequencing-based immune repertoire profiling assays.
  • The DriverMap™ AIR RNA Spike-In Controls' key characteristics include:
    These controls consist of 48 B-Cell Receptor (BCR) and 39 T-Cell Receptor (TCR) synthetic mRNA constructs designed to mimic all the different and most abundant TCR and BCR genes.
  • These standards and controls will help attain the goal of more reliable and reproducible AIR sequencing (AIR-Seq) data harmonization, interpretation, and sharing.
  • For more information on the DriveMap AIR RNA Spike-In Controls, including introductory pricing, visit www.cellecta.com/DriverMapAIR or email [email protected] .

Myeloid Therapeutics to Showcase In Vivo CAR Data and its Diverse mRNA Platform at AACR

Retrieved on: 
Thursday, April 4, 2024
Vivo, Canadian Aviation Regulations, Patient, Primate, RNA, Fragment crystallizable region, Cancer, Messenger, AACR, Chemokine, Cytokine, Drug development, Safety, Myeloid tissue, NK, LNP, Antigen, Annual general meeting, Vaccine

This advancing study represents the first human trial of any in vivo chimeric antigen receptor (CAR) therapy.

Key Points: 
  • This advancing study represents the first human trial of any in vivo chimeric antigen receptor (CAR) therapy.
  • Myeloid will also share information on its portfolio of immune cell programming CARs.
  • "We are thrilled to continue driving this first in vivo mRNA CAR program forward," said Chief Executive Officer Daniel Getts, Ph.D. "Myeloid is at the forefront of in vivo immune cell programming.
  • To date, Myeloid has demonstrated CAR activity in human cells, and following systemic mRNA/LNP delivery in mouse and non-human primates.

Ariceum Therapeutics to present new radioligand therapy data at American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Thursday, April 4, 2024
Diagnosis, Research, RLT, Radionuclide, UCB, Tissue, Messenger, Abstract (summary), AACR, Therapy, Macrocycle, Poster, Annual general meeting, Peptide, Pharmaceutical industry

The findings describe the selection and initial characterization of macrocyclic peptides against an undisclosed target discovered using UCB's mRNA-display technology platform, ExtremeDiversity™.

Key Points: 
  • The findings describe the selection and initial characterization of macrocyclic peptides against an undisclosed target discovered using UCB's mRNA-display technology platform, ExtremeDiversity™.
  • Macrocyclic peptides are potent ligands for radioligand therapeutics (RLT) that aim to selectively deliver radioisotopes to cancer tissues to eradicate tumor cells while limiting the damage to surrounding tissues.
  • These data have positive implications for the future development of RLT and are a potential game-changer in precision cancer therapy.
  • AACR's Annual Meeting is the perfect industry forum at the forefront of cancer research at which to present our findings."

Ariceum Therapeutics to present new radioligand therapy data at American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Thursday, April 4, 2024
Diagnosis, Research, RLT, Radionuclide, UCB, Tissue, Messenger, Abstract (summary), AACR, Therapy, Macrocycle, Poster, Annual general meeting, Peptide, Pharmaceutical industry

The findings describe the selection and initial characterization of macrocyclic peptides against an undisclosed target discovered using UCB's mRNA-display technology platform, ExtremeDiversity™.

Key Points: 
  • The findings describe the selection and initial characterization of macrocyclic peptides against an undisclosed target discovered using UCB's mRNA-display technology platform, ExtremeDiversity™.
  • Macrocyclic peptides are potent ligands for radioligand therapeutics (RLT) that aim to selectively deliver radioisotopes to cancer tissues to eradicate tumor cells while limiting the damage to surrounding tissues.
  • These data have positive implications for the future development of RLT and are a potential game-changer in precision cancer therapy.
  • AACR's Annual Meeting is the perfect industry forum at the forefront of cancer research at which to present our findings."

BioVaxys Announces Allowance of DPX Formulation Patent for the United States and Filing of Additional International Patent Applications for Phase 1 DPX SurMAGE

Retrieved on: 
Wednesday, April 3, 2024
Aggression, A9, Immunotherapy, Patent, Infection, Patient, Lung, Neoplasm, Epitope, IMV, FRA, Cancer, Messenger, Bladder cancer, Protein, Trial of the century, CHU, APC, European, Antibody, Immune system, Kidney, Intellectual property, Therapy, Antigen, Peptide, Vaccine

DPX™ is a proprietary lipid-based delivery platform with no aqueous component that can be formulated with a range of packaged antigens, proteins, peptides, mRNA, or small molecules.

Key Points: 
  • DPX™ is a proprietary lipid-based delivery platform with no aqueous component that can be formulated with a range of packaged antigens, proteins, peptides, mRNA, or small molecules.
  • Its unique "no release" mechanism of action allows antigen presenting cells (APCs) to be attracted to the injection site, facilitating a robust and sustained immune response.
  • BioVaxys President and Chief Operating Officer Kenneth Kovan stated "Allowance of this important patent in the United States greatly expands the value of our IP and antigen delivery platform with potential partners.
  • We will be reconvening with the study team at CHU de Québec-Université Laval to plan further development."

Therapeutic mRNA Patent Monitoring Service 2024: Track Competitors' IP Activities and their Future Intentions

Retrieved on: 
Tuesday, April 2, 2024
PDF, Q&A, COVID-19, DSM-IV codes, Knowledge, RNA, Messenger, Tropism, IP, Cancer, Vaccination, Invention, Pharmacokinetics, Patent, Microsoft Excel, Therapy, Vaccine, Orientation, Directory

The directory includes new patent applications, new granted patents, patents expired/abandoned, patent transfers (re-assignment, licensing), and patent litigation/opposition.

Key Points: 
  • The directory includes new patent applications, new granted patents, patents expired/abandoned, patent transfers (re-assignment, licensing), and patent litigation/opposition.
  • The success of mRNA vaccines as a response to the COVID-19 pandemic has shone a light on the disruptive aspect of mRNA-based therapeutic technology.
  • With the help of the patent monitoring service, you will be aware of your competitors' current patenting activities, their IP dynamics, patent transfers including acquisitions and licenses, patent litigation, technology development, and R&D strategies.
  • Main patent applicants and their inventions, blocking patents, promising patents, and key newly expired or abandoned patents will be highlighted
    Featured image of Therapeutic mRNA patent monitor.

Novavax Presents Data on Updated COVID-19 Vaccine and Progress to Date on its COVID-19-Influenza Combination Vaccine Candidate at World Vaccine Congress 2024

Retrieved on: 
Monday, April 1, 2024
CIC, COVID-19, Immunoglobulin G, Research, WVC, Novavax, NVAX, Messenger, Vaccine

New data from Novavax's ongoing research on its updated XBB.1.5 COVID-19 vaccine in participants who previously received an mRNA vaccine showed robust neutralizing antibody titers for the XBB.1.5 subvariant as well as for the currently circulating JN.1 subvariant.

Key Points: 
  • New data from Novavax's ongoing research on its updated XBB.1.5 COVID-19 vaccine in participants who previously received an mRNA vaccine showed robust neutralizing antibody titers for the XBB.1.5 subvariant as well as for the currently circulating JN.1 subvariant.
  • Data also showed that the vaccine's safety and reactogenicity profile was consistent with its prototype vaccine (NVX-CoV2373).
  • Differences observed in immunoglobulin (IgG) subclass responses and Fcγ-mediated effector functions following mRNA and protein-based COVID-19 vaccinations will be shared.
  • Novavax will also discuss its influenza and CIC vaccine candidates, including a recap of data to date and the timeline for the Phase 3 trial anticipated to start during the second half of 2024.

Open Call: Vilcek Foundation to Award $150,000 in Prizes to Immigrant Scientists in 2025

Retrieved on: 
Monday, March 25, 2024
IRS, Culture, Organization, Rheumatoid arthritis, Gene editing, Foundation (nonprofit), Humanities, Biomedical Research, Vilcek Foundation, Research, History, Messenger, Jan Vilček, Nobel Prize, Biomedical sciences, CRISPR, Creative, Therapy, Family, Parent, Medicine, Pharmaceutical industry

NEW YORK, March 25, 2024 /PRNewswire/ -- The Vilcek Foundation has announced an open call for applications for the 2025 Vilcek Prizes for Creative Promise in Science. Three prizes of $50,000 each will be awarded to young immigrant scientists in the United States whose early career work represents a significant contribution to their field. Applications will be accepted through June 10, 2024, at 5:00pm ET.

Key Points: 
  • The Vilcek Foundation will accept applications for the 2025 Vilcek Prizes for Creative Promise in Biomedical Science through June 10, 2024.
  • NEW YORK, March 25, 2024 /PRNewswire/ -- The Vilcek Foundation has announced an open call for applications for the 2025 Vilcek Prizes for Creative Promise in Science .
  • The Vilcek Prizes for Creative Promise are awarded to immigrant professionals living and working in the United States.
  • The Vilcek Prizes for Creative Promise are a part of the Vilcek Foundation Prizes program.

Fluent Biosciences announces early access availability of transformative direct-guide capture for single cell analysis for complex CRISPR screening in Particle-templated Instant Partitions (PIPseq-CRISPR)

Retrieved on: 
Thursday, March 21, 2024
Single-cell analysis, Stanford University, Doctor of Philosophy, Fluency, Cell, Messenger, CRISPR

WATERTOWN, Mass., March 21, 2024 /PRNewswire/ -- Fluent BioSciences, a life sciences company focused on making single-cell analysis simple and accessible to every researcher, announces early access availability of new kits and reagents for direct CRISPR guide capture in particle templated instant partitions (PIPseq-CRISPR).

Key Points: 
  • WATERTOWN, Mass., March 21, 2024 /PRNewswire/ -- Fluent BioSciences, a life sciences company focused on making single-cell analysis simple and accessible to every researcher, announces early access availability of new kits and reagents for direct CRISPR guide capture in particle templated instant partitions (PIPseq-CRISPR).
  • The PIPseq platform provides an instrument and microfluidics-free approach for single cell analysis, eliminating barriers to accessibility and program costs that limit routine application of high-throughout single cell analysis.
  • These early access kits allow for universal capture of CRISPR guide-RNA in addition to 3' mRNA capture from single-cell suspensions, enabling complex perturbation screening at unprecedented scale and cost.
  • For more information or consideration for early access evaluation of PIPseq-CRISPR reagents, please contact us [email protected] .